Shares of Silexion Therapeutics Corp (NASDAQ: SLXN) experienced a significant surge in premarket trading, rising 52.59% to $2.06 following the release of promising preclinical study results. Over the past week, SLXN has recorded a gain exceeding 70% on ST screener, placing it among the top-performing biotechnology stocks.
While SLXN has shown impressive momentum, other biotech firms, including DOMH and ELTX, have demonstrated even higher price performance. To get more insight about similar stock, visit our screener link.
Significant Progress in the Treatment of Pancreatic Cancer
Silexion Therapeutics revealed promising preclinical results for SIL-204, a next-generation small interfering RNA (siRNA) therapeutic candidate. The study highlights the efficacy of systemic administration as a viable delivery mechanism, showcasing a marked reduction in tumor growth within orthotopic pancreatic cancer models—an approach designed to closely replicate human disease progression.
These findings underscore the potential of SIL-204 in addressing one of the most aggressive forms of cancer, particularly through its targeted inhibition of KRAS mutations, which play a crucial role in tumor development.
Preclinical Success and Future Development Plans
The latest data reveal that SIL-204, when delivered in an extended-release formulation, led to approximately 50% tumor growth reduction over 30 days, with half of the treated tumors exhibiting complete necrosis in xenografted human pancreatic tumors containing the G12D mutation.
Furthermore, in mice with metastatic pancreatic cancer models, subcutaneous administration of SIL-204 effectively inhibited tumor progression; additionally, a single systemic dose maintained effective drug levels in plasma and tissues for more than 56 days, demonstrating sustained therapeutic activity against KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D.
Broadening the Scope of Cancer Treatment
With these encouraging results, Silexion Therapeutics is now focused on utilizing them to improve and broaden its approach to treating KRAS-driven cancers. The company expects to release more information about its comprehensive development plan soon.
SIL-204 has demonstrated its promise as a game-changing treatment for pancreatic and other advanced malignancies by successfully targeting important oncogenic pathways. In this difficult treatment environment, the business is certain that it can prevent metastatic progression and enhance patient outcomes as research advances.